Samer Al Hadidi Institution Verified
Sourced from institutional research profiles (UAMS TRI or ARA).
Associate Professor , Clinical Director of Amyloidosis Program
University of Arkansas for Medical Sciences
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Samer Al Hadidi, M.D., M.S., holds an Associate Professor position and directs the Amyloidosis Program at the University of Arkansas for Medical Sciences. His clinical and research activities focus on plasma cell disorders, including multiple myeloma and light chain amyloidosis, as well as cellular therapies such as CAR T-cell therapy and hematopoietic stem cell transplantation. Dr. Al Hadidi earned his medical degree from the University of Jordan School of Medicine and completed his internal medicine residency at Hurley Medical Center/Michigan State University. He furthered his training with a hematology and oncology fellowship at Baylor College of Medicine and obtained a master's degree in clinical research and statistical analysis from the University of Michigan.
Dr. Al Hadidi is certified by the American Board of Internal Medicine in internal medicine, hematology, and medical oncology. He has published extensively on multiple myeloma and related conditions, with recent work investigating the risk of infections associated with bispecific antibodies, the efficacy of teclistamab in relapsed refractory multiple myeloma, and disparities in access to CAR T-cell and bispecific antibody trials for multiple myeloma. His research also explores the immune microenvironment in multiple myeloma progression. He maintains a significant network of collaborators, including Maurizio Zangari, Sharmilan Thanendrarajan, Carolina Schinke, and Frits van Rhee, all based at the University of Arkansas for Medical Sciences, with whom he has co-authored numerous publications.
His scholarly output includes 240 publications, with an h-index of 19 and over 1,500 citations. Dr. Al Hadidi's work contributes to understanding and improving treatments for hematological malignancies, with a particular emphasis on patient outcomes and access to novel therapies.
Metrics
- h-index: 19
- Publications: 240
- Citations: 1,523
Selected Publications
- Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025) DOI
- Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review (2025) DOI
- Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages (2024) DOI
- Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024) DOI
- Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab (2024) DOI
- Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma (2024) DOI
- Bispecific antibodies and autologous chimeric antigen receptor TÂ cell therapies for treatment of hematological malignancies (2024) DOI
- Industry Payments to Physicians Endorsing Drugs and Devices on a Social Media Platform (2024) DOI
- Targeting GPRC5D in multiple myeloma (2024) DOI
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study (2024) DOI
- Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma (2024) DOI
- Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024) DOI
- Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI
- Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023) DOI
- Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study (2023) DOI
Grants & Funding
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics